← Back to Search

Corticosteroid

Telehealthcare MTM for Asthma (MATCH Trial)

N/A
Waitlist Available
Led By Kathryn Blake, Pharm.D
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 12 through 35 years
Any activity limitation due to asthma; OR Asthma Control Test score ≤19
Must not have
Currently uses an ICS not compatible with the Propeller sensor
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial uses video calls and sensors to help young people with asthma take their medication regularly. It targets those who struggle with sticking to their prescribed treatment, aiming to improve their health by providing support and reminders.

Who is the study for?
This trial is for young adults aged 12-35 with uncontrolled asthma and poor medication adherence. Participants must have an Asthma Control Test score ≤19 or experience significant symptoms, use a compatible inhaler, speak English or Spanish, and be able to engage in telehealthcare.
What is being tested?
The MATCH study tests if Telehealthcare Medication Therapy Management (MTM) via video calls and Electronic Adherence Self-Management (EAM) can improve medication adherence in adolescents and young adults with poorly controlled asthma.
What are the potential side effects?
Since the interventions involve management techniques rather than medications, direct side effects are not expected. However, participants may experience discomfort or privacy concerns related to using technology for health monitoring.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 12 and 35 years old.
Select...
My asthma limits my activities or my Asthma Control Test score is 19 or less.
Select...
I use my rescue inhaler more than twice a week for symptoms.
Select...
My asthma is uncontrolled, showing symptoms or limitations frequently.
Select...
I have been diagnosed with asthma and have no other lung diseases.
Select...
I experience asthma symptoms more than twice a week during the day.
Select...
I have been on inhaled corticosteroids for at least 3 months.
Select...
I use an albuterol inhaler for sudden asthma symptoms.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My inhaler is not compatible with the Propeller sensor.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Proportion of adherent days as assessed by Propeller sensors
Time (days) to first exacerbation event

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: MTM-EAMExperimental Treatment2 Interventions
Medication Therapy Management Video Telehealthcare plus Electronic Adherence Self-Management \[MTM-EAM\]
Group II: EAM onlyActive Control1 Intervention
Electronic Adherence Self-Management \[EAM\] only

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common asthma treatments include inhaled corticosteroids (ICS), long-acting beta agonists (LABA), and long-acting muscarinic antagonists (LAMA). ICS work by reducing inflammation in the airways, LABAs relax the muscles around the airways to improve airflow, and LAMAs block muscarinic receptors to prevent bronchoconstriction. These mechanisms are vital for asthma patients as they help manage symptoms, prevent exacerbations, and improve lung function, thereby enhancing quality of life and reducing the risk of hospitalizations.

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor
2,321 Previous Clinical Trials
14,873,641 Total Patients Enrolled
Nemours Children's Health SystemOTHER
9 Previous Clinical Trials
17,096 Total Patients Enrolled
American Lung AssociationOTHER
31 Previous Clinical Trials
10,673 Total Patients Enrolled

Media Library

Inhaled corticosteroid (ICS) (Corticosteroid) Clinical Trial Eligibility Overview. Trial Name: NCT03978936 — N/A
Young Adults Research Study Groups: EAM only, MTM-EAM
Young Adults Clinical Trial 2023: Inhaled corticosteroid (ICS) Highlights & Side Effects. Trial Name: NCT03978936 — N/A
Inhaled corticosteroid (ICS) (Corticosteroid) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03978936 — N/A
~10 spots leftby Jan 2025